Search results
Showing 721 to 735 of 1254 results for criteria
Lenalidomide plus dexamethasone for previously untreated multiple myeloma (TA587)
Evidence-based recommendations on lenalidomide (Revlimid) plus dexamethasone for previously untreated multiple myeloma in adults.
Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (TA439)
Evidence-based recommendations on cetuximab (Erbitux) and panitumumab (Vectibix) for previously untreated RAS wild-type metastatic colorectal cancer in adults.
Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (TA428)
Evidence-based recommendations on pembrolizumab (Keytruda) for treating PD-L1-positive non-small-cell lung cancer in adults who have had chemotherapy.
Artificial intelligence (AI)-derived software to help clinical decision making in stroke (HTG708)
Evidence-based recommendations on artificial intelligence-derived software to help clinical decision making in stroke.
NICE has developed a Medtech Innovation Briefing (MIB) on the Space GlucoseControl system for managing blood-glucose in critically ill patients in intensive care
NICE has developed a medtech innovation briefing (MIB) on Peptest for diagnosing gastro-oesophageal reflux
This guideline covers the components of a good patient experience. It aims to make sure that all adults using NHS services have the best possible experience of care.
View recommendations for CG138Show all sections
Evidence-based recommendations on raloxifene and teriparatide for preventing osteoporotic fragility fractures in postmenopausal women who have osteoporosis.
View recommendations for TA161Show all sections
NICE has developed a Medtech Innovation Briefing (MIB) on the OSCAR 3 ultrasonic arthroplasty revision instrument for removing bone cement during prosthetic
Evidence-based recommendations on 2 adjunctive colposcopy technologies (the DYSIS colposcope with DYSISmap and the ZedScan I) for assessing suspected cervical abnormalities in people having colposcopy.
Evidence-based recommendations on dinutuximab beta (Qarziba) for high-risk neuroblastoma in people aged 12 months and over.
Evidence-based recommendations on elacestrant (Korserdu) for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment in adults.
Evidence-based recommendations on niraparib (Zejula) for maintenance treatment of advanced (FIGO stages 3 and 4) ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy in adults.
Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA595)
Evidence-based recommendations on dacomitinib (Vizimpro) for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in adults.
Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis (TA254)
Evidence-based recommendations on fingolimod (Gilenya) for highly active relapsing-remitting multiple sclerosis.